Valeant ups bid for Dendreon's Provenge to $400m
Valeant Pharmaceuticals has increased its bid by more than $100m to acquire the personalized prostate cancer immunotherapy Provenge (sipuleucel-T) and other Dendreon assets for $400m.
Valeant Pharmaceuticals has increased its bid by more than $100m to acquire the personalized prostate cancer immunotherapy Provenge (sipuleucel-T) and other Dendreon assets for $400m.